Atavistik Bio Inc.

https://www.atavistikbio.com

LinkedIn: https://www.linkedin.com/company/atavistik-bio

Atavistik Bio (Atavistik) is a pre-clinical stage biotechnology company pioneering the identification of allosteric small molecule-protein interactions that have the potential to lead to the discovery and future clinical development of first-in-class drug compounds within oncology and metabolic diseases. Atavistik was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Led by an experienced management team and advisors, plus a robust investment syndicate, Atavistik is positioned to deliver transformational science to ultimately improve patient care. *

	Start	2021-08-24 existent
	Industry	mass spectrometry technology
	Industry 2	drug discovery
	Person	Josey, John A. (Atavistik Bio 202108 Acting CEO + Venture Partner at Column Group before Peloton Therapeutics)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	75 Sydney Street 4th Floor
	City	02139 Cambridge, MA
		Address record changed: 2023-03-23

Basic data	Employees	n. a.

		* Document for »About Section«: Atavistik Bio Inc.. (8/24/21). "Press Release: Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer". Cambridge, MA.

		Record changed: 2023-09-21

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Atavistik Bio Inc.

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com